Daiichi Sankyo’s ADC DS-8201a Well-Tolerated in PI

Daiichi Sankyo said on October 11 that its HER2-targeting antibody drug conjugate (ADC) DS-8201a was well-tolerated with no dose-limiting toxicities in a PI study enrolling patients with HER2-expressing breast and gastric cancer. In a dose escalation part of the PI...read more